Tag: Martin Shkreli

Study 329 Trick, Treat or Treximet

Regulators seem all too happy to license ever more dangerous variations or combinations of older drugs already on the market and causing serious problems. This willingness has offered an opening for financial speculators to make a killing speculating on the likely profits these drugs could yield, and getting out of the game before much happens.

“Look Beyond Martin Shkreli for Pharma Reform”

Martin Shkreli, the former hedge fund manager who became infamous for buying a life-saving drug and then raising the price significantly, was led away in handcuffs by the FBI last week. Unfortunately, the Boston Globe editorial board reminds us, “viewing his much-publicized takedown as anything like a tipping point in the push for pharmaceutical industry reform would be a mistake.”